Education
About Us
Working with TipRanks
Follow Us
Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹903.10 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹42.26B
Enterprise Value₹47.39B
Total Cash (Recent Filing)₹952.40M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)12.5
Beta1.51
Next Earnings
Apr 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)9.10
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.21
Price to Sales (P/S)3.14
P/FCF Ratio32.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow RecoveryTurning free cash flow positive in 2025 with strong operating cash conversion signals durable internal funding for operations. This improves the company's ability to fund R&D, capex and working capital from operations, lowering dependence on external financing and enhancing long-term financial flexibility.
Margin StrengthHealthy and improving gross, EBIT, EBITDA and net margins demonstrate operational efficiency and likely pricing power. Sustained margins provide resilience through industry cycles, supporting reinvestment in product development and improving the durability of profitability even if top-line growth fluctuates.
Improved Balance SheetAn improved equity ratio, reduced financial leverage and solid return on equity indicate a stronger capital structure and efficient use of shareholders' funds. These attributes enhance the company's capacity to absorb shocks and finance strategic initiatives, strengthening medium-term solvency and resilience.
Bears Say
Substantial Total DebtDespite better leverage metrics, the absolute level of debt remains substantial and raises persistent interest and refinancing risk. High debt can constrain capital allocation, increase cost of capital, and amplify downside in revenue downturns, making debt management a lasting strategic vulnerability.
Volatile Revenue GrowthHistorical volatility in revenue growth and a recent negative growth metric reduce visibility into future cash flows and complicate planning for commercialization and R&D. Persistent top-line variability undermines predictability of earnings, making long-term forecasting and investment pacing more challenging.
Reliance On Partnerships & GrantsMaterial dependence on partnerships, licensing and grants introduces counterparty, concentration and funding-cycle risk. External collaborations can create lumpy, timing-sensitive revenue streams and limit Epigral's control over commercial execution, weakening the durability of revenue growth.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹903.10 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹42.26B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Apr 27, 2026 which is in 69 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on Jan 30, 2026. The company reported ₹9.1 earnings per share for the quarter, beating the consensus estimate of ₹7.3 by ₹1.8.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹9.1 in its last earnings report, beating expectations of ₹7.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―